Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Clinical Rheumatology
|
July 14, 2007
Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin
Lisa Francis, Eduardo Bonilla, Ekaterina Soforo, et al.
Clinical Immunology (Orlando, Fla.)
|
May 22, 2007
Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients
Eduardo Bonilla, Lisa Francis, Fatme Allam, et al.
Arthritis and Rheumatism
|
February 13, 2013
Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus
Ricardo J Garcia, Lisa Francis, Maha Dawood, et al.
Journal of Anaesthesiology, Clinical Pharmacology
|
April 13, 2018
Intraoperative neurophysiological monitoring team's communiqué with anesthesia professionals
Anurag Tewari, Lisa Francis, Ravi N Samy, et al.
Clinical Immunology (Orlando, Fla.)
|
July 11, 2015
Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus
Yuxin Liu, Jianghong Yu, Zachary Oaks, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 6, 2013
Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus
Zhi-Wei Lai, Rebecca Borsuk, Ashwini Shadakshari, et al.
Lancet (London, England)
|
March 20, 2018
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
Zhi-Wei Lai, Ryan Kelly, Thomas Winans, et al.
Arthritis and Rheumatism
|
May 3, 2012
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial
Zhi-Wei Lai, Robert Hanczko, Eduardo Bonilla, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Clinical Rheumatology
|
July 14, 2007
Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin
Lisa Francis, Eduardo Bonilla, Ekaterina Soforo, et al.
Clinical Immunology (Orlando, Fla.)
|
May 22, 2007
Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients
Eduardo Bonilla, Lisa Francis, Fatme Allam, et al.
Arthritis and Rheumatism
|
February 13, 2013
Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus
Ricardo J Garcia, Lisa Francis, Maha Dawood, et al.
Journal of Anaesthesiology, Clinical Pharmacology
|
April 13, 2018
Intraoperative neurophysiological monitoring team's communiqué with anesthesia professionals
Anurag Tewari, Lisa Francis, Ravi N Samy, et al.
Clinical Immunology (Orlando, Fla.)
|
July 11, 2015
Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus
Yuxin Liu, Jianghong Yu, Zachary Oaks, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 6, 2013
Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus
Zhi-Wei Lai, Rebecca Borsuk, Ashwini Shadakshari, et al.
Lancet (London, England)
|
March 20, 2018
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
Zhi-Wei Lai, Ryan Kelly, Thomas Winans, et al.
Arthritis and Rheumatism
|
May 3, 2012
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial
Zhi-Wei Lai, Robert Hanczko, Eduardo Bonilla, et al.
Page
of 2